Lipid emulsion for parenteral nutrition comprising GPC
AssigneesBaxter International Inc., Baxter Healthcare S.A.
InventorsLaurent Jeannin, Julien Hecq
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to parenteral nutritional formulations, including ready-to-use parenteral nutrition formulations. More particularly, the present disclosure is directed to lipid formulations or emulsions and multi-chamber containers comprising same, wherein the lipid emulsion contains glycerophosphorylcholine as a choline source. The present disclosure further relates to methods of providing choline to a patient in need of parenteral nutrition and methods of avoiding and/or treating choline deficiency and liver damage.
Claims25
A lipid emulsion for parenteral administration, comprising (1) glycerophosphocholine (GPC) in a concentration of from 0.1 g to 15.0 g per liter, (2) docosahexaenoic acid (DHA) and (3) arachidonic acid (ARA),
- wherein the lipid emulsion comprises an aqueous phase and between 5% to about 35% by weight of an oil phase based on the total weight of the lipid emulsion,
- wherein the lipid emulsion comprises the DHA in a concentration of from 0.1 g to 5.0 g per 100 g of the oil phase and the ARA in a concentration of from 0.1 g to 15.0 g per 100 g of the oil phase for use in the treatment of choline deficiency and liver damage by parenteral administration, and
- wherein the lipid emulsion is essentially free of eicosapentaenoic acid (EPA).
A parenteral nutrition composition comprising a lipid emulsion, the lipid emulsion comprising:
- (1) glycerophosphocholine (GPC) in a concentration of from 0.1 g to 15.0 g per liter, (2) docosahexaenoic acid (DHA) and (3) arachidonic acid (ARA),
- wherein the lipid emulsion comprises an aqueous phase and between 5% to about 35% by weight of an oil phase based on the total weight of the lipid emulsion,
- wherein the lipid emulsion comprises the DHA in a concentration of from 0.1 g to 5.0 g per 100 g of the oil phase and the ARA in a concentration of from 0.1 g to 15.0 g per 100 g of the oil phase for use in the treatment of choline deficiency and liver damage by parenteral administration, and
- wherein the lipid emulsion is essentially free of eicosapentaenoic acid (EPA).
A parenteral nutrition composition reconstituted from a multi-chamber container comprising an amino acid formulation, a carbohydrate formulation, and a lipid formulation,
- wherein glycerophosphocholine is present in the lipid formulation of the composition in a concentration of from 0.01 g to 6.0 g per liter,
- wherein the lipid formulation further comprises docosahexaenoic acid (DHA) in a concentration of from 0.1 g to 5.0 g per 100 g of the oil phase and arachidonic acid (ARA) in a concentration of from 0.1 g to 15.0 g per 100 g of the oil phase for use in the treatment of choline deficiency and liver damage by parenteral administration, and
- wherein the lipid formulation is essentially free of eicosapentaenoic acid (EPA).
Dependencies are inferred from the claim text.